Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024813 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04024813: Clinical Trial Phase 2 study, sponsored by Gilead Sciences.
NCT04024813 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04024813, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
Interventions
- DRUG Seladelpar
- DRUG Placebo to match Seladelpar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
Why NCT04024813 stopped before completion
NCT04024813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Seladelpar is the first listed.
NCT04024813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04024813 about?
NCT04024813 is a clinical study titled "A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC". The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
What is the current status of trial NCT04024813?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-11-12. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT04024813?
The interventions under investigation include: Seladelpar (DRUG), Placebo to match Seladelpar (DRUG).
Who is sponsoring clinical trial NCT04024813?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04024813's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI